DRUG Bright Minds Biosciences Inc.

CNQ · CA · Healthcare · Biotechnology · brightmindsbio.com

70.59CAD-0.49%Mkt Cap: 507.09M $P/E: —3d ago

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which ar…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap507.09M USD

Enterprise Value282.96M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-8.91M USD

Revenue/Share—

Last Price70.59 CAD

Fiscal Year EndSep 2025

MR QuarterJun 2026

Employees26

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-8.61

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B2.26

EPS (TTM)-2.84

EPS (Forward)-8.20

52W Range

53.9914% of range170.00

52W High170.00 CAD

52W Low53.99 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-14.91%

ROA-14.49%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-6.33M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-2.70%

Net Debt-224.13M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity0.00

Current Ratio121.97

Quick Ratio121.44

Book Value/Sh31.20 CAD

Cash/Share31.21 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split1:5

Split DateJul 14, 2023

Analyst Consensus

Rating1.1 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)133.50 CAD

Upside (mean)+89.1%

Target Range115.00 CAD – 147.00 CAD

115.00+89.1% to mean147.00

# Analysts4

Ownership

Shares Out.9.86M

Float6.69M

Insiders11.94%

Institutions94.88%

Short Interest

Short Ratio5.0d

Short % Float0.04%

Short % Out.0.03%

Shares Short3.10K

Short (prev mo.)4.99K

Technical

SMA 5096.41 (-26.8%)

SMA 200105.88 (-33.3%)

Beta-0.11

S&P 52W Chg14.58%

Avg Vol (30d)782

Avg Vol (10d)507

Technical Indicators

RSI (14)29.2

MACD-8.1537

MACD Signal-5.6896

MACD Hist.-2.4642

BB Upper119.60 CAD

BB Middle89.83 CAD

BB Lower60.05 CAD

BB Width66.30%

ATR (14)4.188 CAD

Vol Ratio (20d)1.08x